Azolium and purinium salt anticancer and antimicrobial agents

US9278951B2 · kind B2 · utility

Assignee

• THE UNIVERSITY OF AKRON · US

Inventors

• Wiley J. Youngs · Akron, US
• Matthew Panzner · Akron, US
• Claire A. Tessier · Akron, US
• Michael Deblock · Akron, US
• Brian J. Wright · Chelmsford, GB
• Patrick Wagers · Akron, US
• Nikki Robishaw · Rittman, US

Key dates

• Filing date: Apr 30, 2012
• Grant date: Mar 8, 2016
• Expiry date: Apr 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplatin.